Earlier this month, Intellia Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, updating investors on its gene-editing pipeline and corporate progress. At ...
Stocktwits on MSN
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD
On Thursday, ARK bought a total of 56,769 shares of Intellia, with 48,178 shares purchased by its ARKK ETF and 8,591 shares ...
ATTR program on hold amid safety risks; HAE therapy faces tough rivals and small market. Read more analysis here.
Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public ...
Zacks Investment Research on MSN
Intellia stock declines around 55% in 3 months: Here's why
Shares of Intellia Therapeutics NTLA have plunged 55.2% over the past three months.The steep decline follows a significant ...
Cathie Wood’s ARK ETF published their daily trades for Tuesday, January 13th, 2026, focusing on a continued accumulation of Intellia Therapeutics Inc (NASDAQ:NTLA). ARK purchased a total of 40,067 ...
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price lowered by Chardan Capital from $91.00 to $68.00 in a report published on Friday morning,Benzinga reports. The brokerage ...
Cathie Wood’s ARK ETF published their daily trades for Thursday, January 15, 2026, revealing a continued focus on Intellia Therapeutics Inc (NASDAQ:NTLA). The firm purchased a total of 56,769 shares ...
Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback